Nanoencapsulation of Antitumor and Antituberculosis Drug Preparations with Biocompatible Polymers

M. Zh. Burkeev; J. Kreuter; A. Van Herk; Y. M. Tazhbayev; L. Zh. Zhaparova; T. S. Zhumagalieva; N. K. Zhappar

doi:10.6000/1929-5995.2014.03.02.2

Authors

M. Zh. Burkeev Karaganda State University named after E.A. Buketov, Universitetskaya street 28, 100028 Karaganda, Kazakhstan
J. Kreuter Institute of Pharmaceutical Technology, Biocenter Niederursel, Johann Wolfgang Goethe University, Max-von-Laue-Straβe 9, D-60438 Frankfurt/Main, Germany
A. Van Herk Eindhoven University of Technology, Polymer Reaction Engineering, the Netherlands
Y. M. Tazhbayev Karaganda State University named after E.A. Buketov, Universitetskaya street 28, 100028 Karaganda, Kazakhstan
L. Zh. Zhaparova Karaganda State University named after E.A. Buketov, Universitetskaya street 28, 100028 Karaganda, Kazakhstan
T. S. Zhumagalieva Karaganda State University named after E.A. Buketov, Universitetskaya street 28, 100028 Karaganda, Kazakhstan
N. K. Zhappar Karaganda State University named after E.A. Buketov, Universitetskaya street 28, 100028 Karaganda, Kazakhstan

DOI:

https://doi.org/10.6000/1929-5995.2014.03.02.2

Keywords:

Drug delivery systems, nanoparticles, nanocapsules, polyalkyl cyanoacrylates, human serum albumin, poly-D, L-lactic acid.

Abstract

Controlled release of drugs at the locus of the targeted disease is one of the most challenging research areas in the pharmaceutical field. Nowadays novel drug delivery systems on the basis of polymers are attracting great attention since they can improve therapeutic efficiency of potent drug preparations decreasing the risk of side effects. By developing colloidal drug delivery systems such as liposomes/vesicles and polymeric nanoparticles and nanocapsules the pharmacokinetics of the drug can be changed and thus the therapeutic efficiency of the drug can be increased. Nanoparticles with their special characteristics such as small particle size, large surface area and high capacity of carrying biologically active substances offer a number of advantages compared to other colloidal drug delivery systems [1, 2].

Controlled drug release systems are constructed on the basis of natural and biocompatible synthetic polymers. Among the most promising biocompatible polymers human serum albumin (HSA), polyalkyl cyanoacrylates (PACA) and poly-D,L-lactic acid (PLA) are of great importance. Nanoparticles on their basis have been proven to be efficient in treatment of serious and long-termed diseases such as tumors, tuberculosis and bacterial infections [3-126]. Therefore this article is aimed to give a brief review on the research works devoted to the synthesis and investigation of polymeric nanoparticles and nanocapsules based on PACA, HSA and PLA for the past three decades.

References

Kreuter J. Colloidal Drug Delivery Systems. New York: Marcel Dekker; 1994.

Kingsley JD, Dou H, Morehead J, Rabinow B, Gendelman HE, Destache ChJ. Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System. J. Neuroimmune Pharmacol 2006; 1: 340-50. http://dx.doi.org/10.1007/s11481-006-9032-4 DOI: https://doi.org/10.1007/s11481-006-9032-4

Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GYa, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res 1999; 16(10): 1564-69. http://dx.doi.org/10.1023/A:1018983904537 DOI: https://doi.org/10.1023/A:1018983904537

Petri B, Bootz A, Khalansky A, et al. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Control Rel 2007; 117(1): 51-8. http://dx.doi.org/10.1016/j.jconrel.2006.10.015 DOI: https://doi.org/10.1016/j.jconrel.2006.10.015

Brasseur F, Couvreur P, Kante B, Speiser P. Actinomycin D adsorbed on polymethylcyanoacrylate nanoparticles: Increased efficiency against an experimental tumor. Eur J Cancer 1980; 16: 1441-5. http://dx.doi.org/10.1016/0014-2964(80)90053-5 DOI: https://doi.org/10.1016/0014-2964(80)90053-5

Sosnik A, Carcaboso AM, Glisoni RJ, Moretton MA, Chiappetta DA. New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery. Adv Drug Delivery Reviews 2010; 62: 547-59. http://dx.doi.org/10.1016/j.addr.2009.11.023 DOI: https://doi.org/10.1016/j.addr.2009.11.023

Azarmi Sh, Roa WH, Löbenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Delivery Reviews 2008; 60: 863-75. http://dx.doi.org/10.1016/j.addr.2007.11.006 DOI: https://doi.org/10.1016/j.addr.2007.11.006

Kreuter J. Nanoparticles-a historical Perspectives. Int J Pharm 2007; 331: 1-10. http://dx.doi.org/10.1016/j.ijpharm.2006.10.021 DOI: https://doi.org/10.1016/j.ijpharm.2006.10.021

Elvira C, Gallardo A, San Roman J, Cifuentes A. Covalent Polymer-Drug Conjugates. Molecules 2005; 1: 114-25. http://dx.doi.org/10.3390/10010114 DOI: https://doi.org/10.3390/10010114

Venkatesan N, Yoshimitsu J, Ito Y, et al. Liquid filled nanoparticles as a drug delivery tool for protein therapeutics. Biomaterials 2005; 26(34): 7154-63. http://dx.doi.org/10.1016/j.biomaterials.2005.05.012 DOI: https://doi.org/10.1016/j.biomaterials.2005.05.012

Mohanraj VJ, Chen Y. Nanoparticles-A Review. Tropical J Pharm Res 2006; 5(1): 561-73. DOI: https://doi.org/10.4314/tjpr.v5i1.14634

Santhi K, Dhanaraj SA, Koshy M, Ponnusankar S, Suresh B. Study of biodistribution of methotrexate-loaded bovine serum albumin nanospheres in mice. Drug Dev Ind Pharm 2000; 26(12): 1293-6. http://dx.doi.org/10.1081/DDC-100102311 DOI: https://doi.org/10.1081/DDC-100102311

Gelperina SE, Kisich K, Iseman MD, Heifets L. The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis. Amer J Respiratory and Critical Care Medicine 2005; 172: 1487-90. http://dx.doi.org/10.1164/rccm.200504-613PP DOI: https://doi.org/10.1164/rccm.200504-613PP

Skidan I, Gelperina S, Severin S, Gulyaev A. Increase of antibacterial activity of rifampicin towards intracellular infections with the help of biodegradable nanoparticles. Antibiotics and Chemotherapy 2003; 48, №1: 23-6.(in Russian)

Simeonova M, Ivanova G, Enchev V, et al. Physicochemical characterization and in vitro behavior of daunorubicin-loaded poly(butyl cyanoacrylate) nanoparticles. Acta Biomateria 2009; 5: 2109-21. http://dx.doi.org/10.1016/j.actbio.2009.01.026 DOI: https://doi.org/10.1016/j.actbio.2009.01.026

Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res 1997; 14: 1568-73. http://dx.doi.org/10.1023/A:1012126301290 DOI: https://doi.org/10.1023/A:1012126301290

Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 1996; 13: 1838-45. http://dx.doi.org/10.1023/A:1016085108889 DOI: https://doi.org/10.1023/A:1016085108889

Behan N, Birkinshaw C. Preparation of poly(butyl cyanoacrylate) nanoparticles by aqueous dispersion polymerization in the presence of insulin. Macromol Rapid Commun 2001; 22: 3-41. http://dx.doi.org/10.1002/1521-3927(20010101)22:1<41::AID-MARC41>3.0.CO;2-B DOI: https://doi.org/10.1002/1521-3927(20010101)22:1<41::AID-MARC41>3.0.CO;2-B

Simeonova M, Velichkova R, Ivanova G, Enchev V, Abrahams I. Poly(butyl cyanoacrylate) nanoparticles for

topical delivery of 5-fluorouracil. Int J Pharm 2003; 263: 133-40. http://dx.doi.org/10.1016/S0378-5173(03)00373-9 DOI: https://doi.org/10.1016/S0378-5173(03)00373-9

Cariline OS, Birkinshaw C. In vitro degradation of insulin-loaded poly(n-butyl cyanoacrylate) nanoparticles. Biomaterials 2004; 25: 4375-82. http://dx.doi.org/10.1016/j.biomaterials.2003.11.001 DOI: https://doi.org/10.1016/j.biomaterials.2003.11.001

Alonso MJ, Losa C, Calvo P, Vila-Jato JL. Approaches to improve the association of amikacin sulphate to poly(alkylcyanoacrylate) nanoparticles. Int J Pharm 1991; 68: 69-76. http://dx.doi.org/10.1016/0378-5173(91)90128-B DOI: https://doi.org/10.1016/0378-5173(91)90128-B

Page-Clisson ME, Pinto-Alphandary H, Ourevitch M, Andremont A, Couvreur P. Development of ciprofloxacin-loaded nanoparticles: physicochemical study of the drug carrier. J Control Rel 1998; 56: 23-32. http://dx.doi.org/10.1016/S0168-3659(98)00065-0 DOI: https://doi.org/10.1016/S0168-3659(98)00065-0

Alleman E, Gurny R, Doelker E. Drug-loaded nanoparticles-preparation methods and drug targeting issues. Review. Eur J Pharm Biopharm 1993; 39(5): 173-91.

Anisimova YV, Gelperina SI, Peloquin CA, Heifets LB. Nanoparticles as antituberculosis drugs carriers: effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages. J Nanoparticle Res 2000; 2: 165-71. http://dx.doi.org/10.1023/A:1010061013365 DOI: https://doi.org/10.1023/A:1010061013365

Oganesyan EA, Budko AP, Maximenko OO, et al. Development and study of nanosomal drug formulation of rifampicin. Antibiotics and Chemotherapy 2005; 50: 15-9.(in Russian)

Shipulo YV, Lyubimov II, Maximenko OO, et al. Preparation and investigation of nanosomal forms of moksifloxacin on the basis of polybutyl cyanoacrylate. Pharm Chem J 2008; 42: 43-7.(in Russian) DOI: https://doi.org/10.1007/s11094-008-0073-2

Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005; 19: 311-22. http://dx.doi.org/10.1096/fj.04-2747rev DOI: https://doi.org/10.1096/fj.04-2747rev

Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis 2005; 85: 415-20. http://dx.doi.org/10.1016/j.tube.2005.08.009 DOI: https://doi.org/10.1016/j.tube.2005.08.009

Pandey R, Khuller GK. Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J Antimicrobial Chemotherapy 2006; 4: 1-7. DOI: https://doi.org/10.1093/jac/dkl128

Johnson CM, Pandey R, Sharma S, et al. Oral Therapy Using Nanoparticle-Encapsulated Antituberculosis Drugs in Guinea Pigs Infected with Mycobacterium tuberculosis. Antimicrobial agents and Chemotherapy 2005; 49. № 10: 4335-8. DOI: https://doi.org/10.1128/AAC.49.10.4335-4338.2005

Peracchia MT, Desmaele D, Couvreur P. Synthesis of a Novel poly(MePEG cyanoacrylate-co-alkylcyanoacrylate) amphiphilic copolymer for nanoparticle technology. Macromol 1997; 30: 846-51. http://dx.doi.org/10.1021/ma961453k DOI: https://doi.org/10.1021/ma961453k

Cook RO, Pannu RK, Kellaway IW. Novel sustained release microspheres for pulmonary drug delivery. J Control Rel 2005; 104: 79-89. http://dx.doi.org/10.1016/j.jconrel.2005.01.003 DOI: https://doi.org/10.1016/j.jconrel.2005.01.003

Lin X, Zhou R, Qiao Y, et al. Poly(ethylene glycol)/poly(ethyl cyanoacrylate) amphiphilic triblock copolymer nanoparticles as delivery vehicles for dexamethasone. J Polymer Sci: Part A: Polymer Chem 2008; 46: 7809-15. http://dx.doi.org/10.1002/pola.23083 DOI: https://doi.org/10.1002/pola.23083

Grangier JL, Pyugrenier M, Gautier JC, et al. Nanoparticles as carriers for growth hormone releasing factor. J Control Rel 1991; 15: 3-13. http://dx.doi.org/10.1016/0168-3659(91)90098-X

Weber C, Kreuter J, Langer K. Desolvation process and surface characteristics of HSA-nanoparticles. Int J Pharm 2000; 196: 197-200. http://dx.doi.org/10.1016/S0378-5173(99)00420-2 DOI: https://doi.org/10.1016/S0378-5173(99)00420-2

Langer K, Balthasar S, Vogel V, Dinauer N, Schubert von B.D. Optimization of the preparation process for human serum albumin(HSA) nanoparticles. Int J Pharm 2003; 257: 169-80. http://dx.doi.org/10.1016/S0378-5173(03)00134-0 DOI: https://doi.org/10.1016/S0378-5173(03)00134-0

Dreis S, Rothweiler F, Michaelis M, Cinatl Jr, Kreuter J, Langer K. Preparation, characterization and maintenance of drug efficacy of doxorubicin-loaded human serum albumin(HSA) nanoparticles. Int J Pharm 2007; 341: 207-14. http://dx.doi.org/10.1016/j.ijpharm.2007.03.036 DOI: https://doi.org/10.1016/j.ijpharm.2007.03.036

Giovagnoli S, Blasi P, Vescovi C, et al. Unilamellar vesicles as potential capreomycin sulfate carriers: Preparation and Physicochemical Characterization. AAPS Pharm Sci Tech 2003; 4. № 4: 1-12. DOI: https://doi.org/10.1208/pt040469

Kreuter J. Nanoparticles as drug delivery systems. In Nalwa HS, editor. Encyclopedia of Nanoscience and Nanotechnology. American Scientific Publishers, Stevenson Ranch, USA 2004; Vol. 7: p. 161.

Wartlick H, Spänkuch-Schmitt B, Strebhardt K, Kreuter J, Langer K. Tumour cell delivery of antisense oligonulceotides by human serum albumin nanoparticles. J Control Rel 2004; 96: 483-95. http://dx.doi.org/10.1016/j.jconrel.2004.01.029 DOI: https://doi.org/10.1016/j.jconrel.2004.01.029

Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, Langer K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target 2004; 12: 461-71. http://dx.doi.org/10.1080/10611860400010697 DOI: https://doi.org/10.1080/10611860400010697

Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 2009; 71: 251-6. http://dx.doi.org/10.1016/j.ejpb.2008.08.021 DOI: https://doi.org/10.1016/j.ejpb.2008.08.021

Kreuter J, Hekmatara T, Dreis S, Vogel T, Gelperina S, Langer K. Covalent attachment of apolipoprotein AI and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Control Rel 2007; 118: 54-8. http://dx.doi.org/10.1016/j.jconrel.2006.12.012 DOI: https://doi.org/10.1016/j.jconrel.2006.12.012

Langer K, Anhorn MG, Steinhauser I, et al. Human serum albumin(HSA) nanoparticles: Reproducibility of preparation process and kinetics of enzymatic degradation. Pharm Nanotechnology 2007; 347: 109-117. DOI: https://doi.org/10.1016/j.ijpharm.2007.06.028

Bui KT, Alyautdin RN. Polylactide nanoparticles with antituberculosis drugs adsorbed on them. Exp Clin Pharmacology 2008; 3: 7-11. (in Russian)

Сhavany C, Le Doan T, Couvreur P, et al. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. Pharm Res 1992; 9(4): 441-9.

Vauthier С, Dubernet С, Chauvierre С, Brigger I, Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Rel 2003; 93: 151-60. http://dx.doi.org/10.1016/j.jconrel.2003.08.005 DOI: https://doi.org/10.1016/j.jconrel.2003.08.005

Couvreur P, Dubernet C, Paisieux F. Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur J Pharm and Biopharm 1995; 41. № 1: 2-13.

Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. J Drug Target 2008; 16(2): 108-23. http://dx.doi.org/10.1080/10611860701794353 DOI: https://doi.org/10.1080/10611860701794353

Bootz A, Russ T, Gores F, Karas M, Kreuter J. Molecular weights of poly(butyl cyanoacrylate) nanoparticles determined by mass spectrometry and size exclusion chromatography. Eur J Pharm and Biopharm 2005; 60: 391-9. DOI: https://doi.org/10.1016/j.ejpb.2005.02.009

Kreuter J, Wilson CG, Fry JR, Paterson P, Ratcliffe JH. Toxicity and association of polycyanoacrylate nanoparticles with hepatocytes. J Microencapsul 1984; 1: 253-7. DOI: https://doi.org/10.3109/02652048409049364

Kante B, Couvreur P, Dubois-Krack G, et al. Toxicity of polyalkyl cyanoacrylate nanoparticles I: free nanoparticles. J Pharm Sci 1982; 71: 786-90. http://dx.doi.org/10.1002/jps.2600710716 DOI: https://doi.org/10.1002/jps.2600710716

Vansnick L, Couvreur P, Christiaens-Leyh D, Roland M. Molecular weights of free and drug-loaded nanoparticles. Pharm Res 1985; 6: 36-41. http://dx.doi.org/10.1023/A:1016366022712 DOI: https://doi.org/10.1023/A:1016366022712

Kumaresh SS, Tejrai AM, Anadrao KR, et al. Biodegradable polymeric nanoparticles as drug delivery devices. Review. J Control Rel 2001; 70: 1-20. http://dx.doi.org/10.1016/S0168-3659(00)00339-4 DOI: https://doi.org/10.1016/S0168-3659(00)00339-4

Nah JW, Jeong YI, Koh JJ. Drug release from nanoparticles of poly(D,L-lactide-co-glycolide). Korean J Chem Eng 2000; 17(2): 230-6. DOI: https://doi.org/10.1007/BF02707148

Couvreur P, Grislain L, Lenaerts V, Brasseur F, Guiot P, Biernacki A. Biodegradable polymeric nanoparticles as drug carriers for antitumor agents. In: Guiot P, Couvreur P, editors. Polymer Nanoparticles and Microspheres. Boca Raton, FL: CRC Press 1986; p. 24- 94.

Couvreur P, Couarraze G, Devissaguet J, Puisieux F, Nanoparticles: preparation and characterization. In: Benita S, editor. Microencapsulation: Methods and Industrial Applications. New York: Marcel Dekker 1996; p. 183- 211.

Allemann E, Gurny R, Doelker E. Drug-loaded nanoparticles-preparation methods and drug targeting issues. Eur J Pharm and Biopharm 1993; 39: 173-91.

Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 1997; 14: 325-8. http://dx.doi.org/10.1023/A:1012098005098 DOI: https://doi.org/10.1023/A:1012098005098

Krauel K, Pitaksuteepong T, Davies ND, Rades T. Entrapment of bioactive molecules in poly(alkylcyanoacrylate) nanoparticles. Amer J Drug Delivery 2004; 2: 251-8. http://dx.doi.org/10.2165/00137696-200402040-00005 DOI: https://doi.org/10.2165/00137696-200402040-00005

Huang C-Y, Lee Y-D. Core-shell type of nanoparticles composed of poly[(n-butyl cyanoacrylate)-co-(2-octyl cyanoacrylate)] copolymers for drug delivery application: Synthesis, characterization and in vitro degradation. Int J Pharm 2006; 325: 132-9. http://dx.doi.org/10.1016/j.ijpharm.2006.06.008 DOI: https://doi.org/10.1016/j.ijpharm.2006.06.008

Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary P, Couvreur P. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Delivery Reviews 2003; 55: 519-48. http://dx.doi.org/10.1016/S0169-409X(03)00041-3 DOI: https://doi.org/10.1016/S0169-409X(03)00041-3

Arias JL, Gallardo V, Ruiz MA, Delgado AV. Ftorafur loading and controlled release from poly(ethyl-2-cyanoacrylate) and poly(butylcyanoacrylate) nanospheres. Int J Pharm 2007; 337: 282-90. http://dx.doi.org/10.1016/j.ijpharm.2006.12.023 DOI: https://doi.org/10.1016/j.ijpharm.2006.12.023

Charles AP, Shaun EB, Gwen AH, et al. Once-daily and twice-daily dosing of p-aminosalicylic acid granules. Amer J Resp and Crit Care Medicine 1999; 159: 932-4. http://dx.doi.org/10.1164/ajrccm.159.3.9807131 DOI: https://doi.org/10.1164/ajrccm.159.3.9807131

Graf A, McDowell A, Rades Th. Poly(alkycyanoacrylate) nanoparticles for enhanced delivery of therapeutics-is there real potential? Expert Opin. Drug Deliv 2009; 6(4): 371-87. http://dx.doi.org/10.1517/17425240902870413 DOI: https://doi.org/10.1517/17425240902870413

Chavany C, Le Doan T, Couvreur P, Puisieux F, Helene C. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. Pharm Res 1992; 9: 441-9. http://dx.doi.org/10.1023/A:1015871809313 DOI: https://doi.org/10.1023/A:1015871809313

Guise V, Drouin JY, Benoit J, Mahuteau J, Dumont P, Couvreur P. Vidarabine-loaded nanoparticles: A physicochemical study. Pharm Res 1990; 7(7): 736-41. http://dx.doi.org/10.1023/A:1015819706491 DOI: https://doi.org/10.1023/A:1015819706491

Montaseri H, Sayyafan MS, Tajerzadeh H. Preparation and Characterization of Poly-(methyl ethyl cyanoacrylate) Particles Containing 5-Aminosalicylic acid. Iranian J Pharm Res 2005; 1: 21-27.

Reddy HL, Murthy RR. Influence of polymerization technique and experimental variables on the particle properties and release kinetics of methotrexate from poly(butylcyanoacrylate) nanoparticles. Acta Pharm 2004; 54: 103-8.

Liu H, Chen J. Indomethacin-loaded Poly(butylcyanoacrylate) Nanoparticles: Preparation and Characterization. PDA J Pharm Sci and Technology. 2009; 63: 207-16.

Douglas SG, Illum L, Davis SS, Kreuter J. Particle size and size distribution poly(2-butyl)cyanoacrylate nanoparticles. 1. Influence of physicochemical factors. J Colloid and Interface Sci 1984; 101(1): 149-58. http://dx.doi.org/10.1016/0021-9797(84)90015-8 DOI: https://doi.org/10.1016/0021-9797(84)90015-8

Paramonov DV, Antonova YA, Zharova IG, et al. About radiation induced stability of drug forms of ampicillin based on polyalkyl cyanoacrylate nanoparticles. Pharm Chem J 1996; 10: 42-5.(in Russian) DOI: https://doi.org/10.1007/BF02333894

Zara GP, Cavalli R, Fundarò A, Bargoni A, Caputo O, Gasco MR. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres(SLN). Pharmacol Res 1999; 40(3): 281-6. http://dx.doi.org/10.1006/phrs.1999.0509 DOI: https://doi.org/10.1006/phrs.1999.0509

Couvreur P, Vauthier Ch. Nanotechnology: Intelligent Design to treat Complex Disease. Pharm Res 2006; 23(7): 1417-50. http://dx.doi.org/10.1007/s11095-006-0284-8 DOI: https://doi.org/10.1007/s11095-006-0284-8

Löbenberg R, Araujo L, Von Briesen H, Rodgers E, Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J Control Rel 1998; 50(1-3): 21-30. http://dx.doi.org/10.1016/S0168-3659(97)00105-3 DOI: https://doi.org/10.1016/S0168-3659(97)00105-3

Leu D, Manthey B, Kreuter J. Distribution and elimination of coated polymethyl [2-14C]methacrylate nanoparticles after intravenous injection in rats. J Pharm Sci 1984; 73(10): 1433-7. http://dx.doi.org/10.1002/jps.2600731028 DOI: https://doi.org/10.1002/jps.2600731028

Legaroz C, Gamazo C, Renedo MJ, Blanco-Prieto MG. Biodegradable micro- and nanoparticles as long-term delivery vechicles for gentamicin. J Microencapsul 2006; 23(7): 782-92. http://dx.doi.org/10.1080/02652040600946886 DOI: https://doi.org/10.1080/02652040600946886

Сouvreur P, Kante M, Grislain L, et al. Toxicity of polyalkylcyanoacrylate nanoparticles. II. Doxorubicin-loaded nanoparticles. J Pharm Sci 1982; 71: 790-2. http://dx.doi.org/10.1002/jps.2600710717 DOI: https://doi.org/10.1002/jps.2600710717

Vauthier Ch, Labarre D, Ponchel G. Design aspects of poly(alkyl cyanoacrylate) nanoparticles for drug delivery. J Drug Target 2007; 15(10): 641-63. http://dx.doi.org/10.1080/10611860701603372 DOI: https://doi.org/10.1080/10611860701603372

Muller RH, Lherm C, Herbort J, Couvreur P. In vitro model for the degradation of alkylcyanoacrylate nanoparticles. Biomaterials 1990; 11: 590-5. http://dx.doi.org/10.1016/0142-9612(90)90084-4 DOI: https://doi.org/10.1016/0142-9612(90)90084-4

Сouvreur P, Kante M, Roland P, et al. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J Pharm Pharmocol 1979; 31: 331-2. http://dx.doi.org/10.1111/j.2042-7158.1979.tb13510.x DOI: https://doi.org/10.1111/j.2042-7158.1979.tb13510.x

Caruso F. Hollow Capsule Processing through Colloidal Templating and Self-Assembly. Chem Eur J 2000; 6(3): 413-9. http://dx.doi.org/10.1002/(SICI)1521-3765(20000204)6:3<413::AID-CHEM413>3.0.CO;2-9 DOI: https://doi.org/10.1002/(SICI)1521-3765(20000204)6:3<413::AID-CHEM413>3.0.CO;2-9

Fujimoto K, Toyoda T, Fukui Y. Preparation of bionanocapsules by the layer-by-layer deposition of polypeptides onto a liposome. Macromol 2007; 40: 5122-8. http://dx.doi.org/10.1021/ma070477w DOI: https://doi.org/10.1021/ma070477w

Kepczynski M, Lewandowska J, Romek M, Zapotoczny S, Ganachaud F, Nowakowska M. Silicone nanocapsules templated inside the membranes of catanionic vesicles. Langmuir 2007; 23: 7314-20. http://dx.doi.org/10.1021/la063442i DOI: https://doi.org/10.1021/la063442i

Kepczynski M, Ganachaud F, Hemery P. Silicone nanocapsules from catanionic vesicle templates; Adv Mater 2004; 16(20): 1861-3. http://dx.doi.org/10.1002/adma.200400537 DOI: https://doi.org/10.1002/adma.200400537

Fukui Y, Fujimoto K. The preparation of sugar polymer-coated by the layer-by-layer deposition on the liposome. Langmuir, XXXX Amer Chem Society 2009; XXX(XX): 234. DOI: https://doi.org/10.1021/la9008834

Arias JL, Gallardo V, Gomez-Lopera SA, Plaza RC, Delgado AV. Synthesis and characterization of poly(ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. J Control Rel 2001; 77: 309-21. http://dx.doi.org/10.1016/S0168-3659(01)00519-3 DOI: https://doi.org/10.1016/S0168-3659(01)00519-3

Musyanovich A, Landfester K. Synthesis of polybutylcyanoacrylate nanocapsules by interfacial polymerization in miniemulsions for the delivery of DNA molecules. Prog Colloid Polym Sci 2008; 134: 120-7. DOI: https://doi.org/10.1007/2882_2008_089

Gasco MR, Trotta M. Nanoparticles from microemulsions. Int J Pharm 1986; 2: 251-8. DOI: https://doi.org/10.1016/0378-5173(86)90125-0

Watnasirichaikul S, Davies NM, Rades T, Tucker IG. Preparation of biodegradable insulin nanocapsules from biocompatible microemulsions. Pharm Res 2000; 17(6): 684-9. DOI: https://doi.org/10.1023/A:1007574030674

Miyzaki Sh, Takahashi A, Kubo W. Poly-n-butylcyanoacrylate(PNBCA) nanocapsules as a carrier for NSAIDs: in vitro release and in vivo skin penetration. J Pharm Pharmacol 2003; 4: 34-9.

Fresta M, Cavallaro G, Giammona G, Wehrlis E, Puglisi G. Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs. Biomaterials 1996; 17: 751-8. http://dx.doi.org/10.1016/0142-9612(96)81411-6 DOI: https://doi.org/10.1016/0142-9612(96)81411-6

Li G, Guo J, Wang X, Wei J. Microencapsulation of a functional dye and its UV-crosslinking controlled releasing behavior. J Polym Sci Part A Polym. Chem 2009; 47: 3630-9. DOI: https://doi.org/10.1002/pola.23434

Crespy D, Stark M, Hoffmann-Richter C, Ziener U, Landfester K. Polymeric nanoreactors for hydrophilic reagents synthesized by interfacial polycondensation on miniemulsion droplets. Macromol 2007; 40: 3122-35. http://dx.doi.org/10.1021/ma0621932 DOI: https://doi.org/10.1021/ma0621932

Pitaksuteepong T, Davies NM, Tucker IG, et al. Factors influencing the entrapment of hydrophilic compounds in nanocapsules prepared by interfacial polymerization of water-in-oil microemulsions. Eur J Pharm Biopharm 2002; 53: 335-42. http://dx.doi.org/10.1016/S0939-6411(01)00245-4 DOI: https://doi.org/10.1016/S0939-6411(01)00245-4

Van Zul A JP, Bosch RFP, McLeary JB, Sanderson RD, Klumperman B. Synthesis of styrene based liquid-filled polymeric nanocapsules by the use of RAFT-mediated polymerization in miniemulsion. Polymer 2005; 46: 3607-15. http://dx.doi.org/10.1016/j.polymer.2005.03.025 DOI: https://doi.org/10.1016/j.polymer.2005.03.025

Al Khouri FN, Roblot-Treupel L, Fessi H, Devissaguet GP, Puisieux F. Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules. Int J Pharm 1986; 28: 125-32. http://dx.doi.org/10.1016/0378-5173(86)90236-X DOI: https://doi.org/10.1016/0378-5173(86)90236-X

El-Nokali MA, Piatt DM, Charpentier BA. Polymeric Delivery Systems. Properties and Application. ASC. Washington; 1999.

Vauthier Ch., Couvreur P. Biodegradation of poly(alkylcyanoacrylates). BPOL 2000; 1: 1-35.

Plate NA, Vasiliev AE. Physiologically active polymers. Macromol Compounds 1982; 24(4): 675-95.(in Russian) DOI: https://doi.org/10.1016/0032-3950(82)90330-6

Kopecek I. Polymers with controlled biodegradability as carriers of biologically active substances. J All-Soviet Union Chem Society named after D.I. Mendeleyev 1985; 30(4): 372-7. (in Russian)

Tsapis N, Bennett D, O’Driscoll K, et al. Direct lung delivery of para-aminosalicylic acid by aerosol particles. Tuberculosis 2003; 83: 379-85. http://dx.doi.org/10.1016/j.tube.2003.08.016 DOI: https://doi.org/10.1016/j.tube.2003.08.016

Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 2005; 85(4): 227-34. http://dx.doi.org/10.1016/j.tube.2004.11.003 DOI: https://doi.org/10.1016/j.tube.2004.11.003

Grangier JL, Pyugrenier M, Gautier JC, et al. Nanoparticles as carriers for growth hormone releasing factor. J Control Rel 1991; 15: 3-13. http://dx.doi.org/10.1016/0168-3659(91)90098-X DOI: https://doi.org/10.1016/0168-3659(91)90098-X

Lambert G, Fattal E, Pinto-Alphandary H, Gulik A, Couvreur P. Polyisobutyl cyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm Res 2000; 17(6): 707-14. http://dx.doi.org/10.1023/A:1007582332491 DOI: https://doi.org/10.1023/A:1007582332491

Hillaireau H, Doan TLe, Chacun H, Janin J, Couvreur P. Encapsulation of mono- and oligo-nucleotides into aqueous-core nanocapsules in the presence of various water-soluble polymers. Int J Pharm 2007; 331: 148-52. http://dx.doi.org/10.1016/j.ijpharm.2006.10.031 DOI: https://doi.org/10.1016/j.ijpharm.2006.10.031

Liang M, Davies NM, Toth I. Increasing entrapment of peptides within poly(alkyl cyanoacrylate) nanoparticles prepared from water-in-oil microemulsions by copolymerization. Int J Pharm 2006; 362: 141-6. http://dx.doi.org/10.1016/j.ijpharm.2008.06.005 DOI: https://doi.org/10.1016/j.ijpharm.2008.06.005

Clemens KW, Ulrich Z, Landfester K. A Route to Nonfunctionalized and Functionalized Poly(n-butylcyanoacrylate) Nanoparticles: Preparation in Miniemulsion. Macromol 2007; 40: 928-38. http://dx.doi.org/10.1021/ma061865l DOI: https://doi.org/10.1021/ma061865l

Mendez CM, McClain CJ, Marsano LS, Albumin therapy in clinical practice. Nutr Clin Prac 2005; 20: 314-20. http://dx.doi.org/10.1177/0115426505020003314 DOI: https://doi.org/10.1177/0115426505020003314

Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Control Rel 2008; 132: 171-83. http://dx.doi.org/10.1016/j.jconrel.2008.05.010 DOI: https://doi.org/10.1016/j.jconrel.2008.05.010

Derakhshandeh K, Erfan M, Dadashzadeh S. Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics. Eur J Pharm Biopharm 2007; 66(1): 34-41. http://dx.doi.org/10.1016/j.ejpb.2006.09.004 DOI: https://doi.org/10.1016/j.ejpb.2006.09.004

Fonseca C, Simoes S, Gaspar R, Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Rel 2002; 83(2): 273-86. http://dx.doi.org/10.1016/S0168-3659(02)00212-2

Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Rel 2002; 79(1-3): 123-35. http://dx.doi.org/10.1016/S0168-3659(01)00530-2 DOI: https://doi.org/10.1016/S0168-3659(01)00530-2

Pinto MM, Sousa EP, Natural and synthetic xanthonolignoids: chemistry and biological activities. Curr Med Chem 2003; 10(1): 1-12. http://dx.doi.org/10.2174/0929867033368574 DOI: https://doi.org/10.2174/0929867033368574

Nicoli S, Santi P, Couvreur P, Couarraze G, Colombo P, Fattal E. Design of triptorelin loaded nanospheres for

transdermal iontophoretic administration. Int J Pharm 2001; 214(1-2): 31-5. http://dx.doi.org/10.1016/S0378-5173(00)00632-3 DOI: https://doi.org/10.1016/S0378-5173(00)00632-3

Gao H, Wang YN, Fan YG, et al. Synthesis of a biode-gradable tadpole-shaped polymer via the coupling reaction of polylactide onto mono(6-(2-aminoethyl)amino-6-deoxy)-beta-cyclodextrin and its properties as the new carrier of protein delivery system. J Control Rel 2005; 107(1): 158-73. http://dx.doi.org/10.1016/j.jconrel.2005.06.010 DOI: https://doi.org/10.1016/j.jconrel.2005.06.010

Burgess DJ, Davis SS, Tomlinson E. Potential use of albumin microspheres as a drug delivery system. I. Preparation and in vitro release of steroids. Int J Pharm 1987; 39: 129-36. http://dx.doi.org/10.1016/0378-5173(87)90207-9 DOI: https://doi.org/10.1016/0378-5173(87)90207-9

Wunder A, Muller-Ladner U, Stelzer EH, et al. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol 2003; 170: 4793-801. http://dx.doi.org/10.4049/jimmunol.170.9.4793 DOI: https://doi.org/10.4049/jimmunol.170.9.4793

Marty JJ, Oppenheim RC. Colloidal systems for drug delivery. Aust J Pharm Sci 1977; 6: 65-76.

Marty JJ, Oppenheim RC, Speiser P. Nanoparticles-a new colloidal drug delivery system. Pharm Acta Helv 1978; 53: 17-23.

Kufleitner J, Wagner S, Worek F, von Briesen H, Kreuter J. Adsorption of obidoxime onto human serum albumin nanoparticles: Drug loading, particle size and drug release. J Microencapsul 2010; 27(6): 506-13. http://dx.doi.org/10.3109/02652041003681406 DOI: https://doi.org/10.3109/02652041003681406

Kufleitner J, Worek F, Kreuter J. Incorporation of obidoxime into human serum albumin nanoparticles: optimization of preparation parameters for the development of a stable formulation. J Microencapsul 2010; 27(7): 594-601. http://dx.doi.org/10.3109/02652048.2010.501395 DOI: https://doi.org/10.3109/02652048.2010.501395

Sebak S, Mirzael M, Malhotra M, Kulamarva A, Prakash S. Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. Int J Nanomedicine 2010; 5: 525-532. DOI: https://doi.org/10.2147/IJN.S10443

Taheri A, Fatemeh A, Faranak S, et al. Nanoparticles of conjugated Methotrexate-Human Serum albumin: Preparation and cytotoxicity evaluations. J Nanomaterials 2011; 10: 1-7. http://dx.doi.org/10.1155/2011/768201 DOI: https://doi.org/10.1155/2011/768201

El-Samaligy M, Rohdewald P. Triamcinolone diacetate nanoparticles, a sustained release drug delivery system suitable for parenteral administration. Pharm Acta Helv 1982; 57: P. 201.

Kreuter J, Ramge P, Petrov V, et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanopar-ticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 2003; 20: 409-16. http://dx.doi.org/10.1023/A:1022604120952 DOI: https://doi.org/10.1023/A:1022604120952

Ali SI, Heuts JPA, Hawkett BS, van Herk AM. Polymer Encapsulated Gibbsite Nanoparticles: Efficient Preparation of Anisotropic Composite Latex Particles by RAFT-based Starved Feed Emulsion Polymerization. Langmuir 2009; 25(18): 10523-33. http://dx.doi.org/10.1021/la9012697 DOI: https://doi.org/10.1021/la9012697

Ali SI, Heuts JPA, van Herk AM. Controlled Synthesis of Polymeric Nanocapsules by RAFT-based Vesicle Templating. Langmuir 2010; 26(11): 7848-58. http://dx.doi.org/10.1021/la904709c DOI: https://doi.org/10.1021/la904709c

Ali SI, Heuts JPA, van Herk AM. Vesicle-templated pH-responsive polymeric Nanocapsules. Soft Matter 2011; 7: 5382-90. http://dx.doi.org/10.1039/c1sm05266g DOI: https://doi.org/10.1039/c1sm05266g

Shirinskiy VG. Poly-n-butyl cyanoacrylate nanoparticles as carriers of gentamycin to intracellular medium. Medicine and Ecology 1997; № 2: 107-10. (in Russian)

Zhaparova LZh, Tazhbayev YM, Burkeev MZh, Kreuter J, Zhymagalieva TS. Synthesis of polymeric nanoparticles on the basis of butyl cyanoacrylate for transport of antitumor drug preparation “Arglabin”. Herald of Karaganda University, Serial Chem 2011; 1(61): 37-41. (in Russian)

Zhaparova LZh, Tazhbayev YM, Burkeev MZh, et al. Synthesis and Characterization of Polyethylcyanoacrylate nanoparticles loaded with capreomycin sulfate. Pharm Chem J 2012; 46(1): 6-9. http://dx.doi.org/10.1007/s11094-012-0724-1 DOI: https://doi.org/10.1007/s11094-012-0724-1

Chouinard FI, Kan FWK, Leroux JChI, Foucher Ch, Lenaerts V. Preparation and purification of polyisohexylcyanoacrylate nanocapsules. Int J Pharm 1991; 72: 211-7. http://dx.doi.org/10.1016/0378-5173(91)90110-A DOI: https://doi.org/10.1016/0378-5173(91)90110-A

Chouinard FI, Buczkowski S, Lenaerts V. Poly(alkylcy-anoacrylate) nanocapsules: physicochemical characteri-zation and mechanism of formation. Pharm Res 1994; 11(6): 869-74. http://dx.doi.org/10.1023/A:1018938026615 DOI: https://doi.org/10.1023/A:1018938026615

Ryan B, McCann G. Novel sub-ceiling temperature rapid depolymerization-repolymerization reactions of cyanoacrylate polymers. Macromol Rapid Commun 1996; 17: 217-227. http://dx.doi.org/10.1002/marc.1996.030170404 DOI: https://doi.org/10.1002/marc.1996.030170404

Zhaparova L, Tazhbayev Y, Burkeev M, Adekenov S, Ulbrich K, Kreuter J. Preparation and investigation of antitumor drug Arglabin loaded human serum albumin nanoparticles. Trends in Cancer Res 2008; 4: 43-7.

Burkeev M, Tazhbayev Y, Zhaparova L, Kreuter J. Polymeric nanosystems for the delivery of antitumor and antituberculosis drugs. Herald of Kazakh National University 2013; 2(70): 58-64. (in Kazakh) DOI: https://doi.org/10.15328/chemb_2013_258-64

Fonseca С, Simoes S, Gaspar R, Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Rel 2002; 83(2): 273-86. DOI: https://doi.org/10.1016/S0168-3659(02)00212-2

Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Del Reviews 2003; 55: 329-47. http://dx.doi.org/10.1016/S0169-409X(02)00228-4 DOI: https://doi.org/10.1016/S0169-409X(02)00228-4

Panarin YF. Polymers in Medicine and Pharmacy: handbook. Saint-Petersburg: Edition of polytechnic University, 2008. (in Russian)

Zhubanov BA, Batyrbekov EO, Iskakov RM. Polymeric materials with healing properties. Almaty: Complex, 2000. (in Russian)

Fenske DB, Chonn A, Cullis PR. Liposomal nanomedicines: an emerging field. Toxicol. Pathol 2008; 36(1): 21-9. DOI: https://doi.org/10.1177/0192623307310960

Shaitan K, Tourleigh Y, Golik D, Kirpichnikov M. Computer-aided molecular design of nanocontainers for inclusion and targeted delivery of bioactive compounds. J Drug Del Sci Tech 2006; 16: 253-8. DOI: https://doi.org/10.1016/S1773-2247(06)50047-4

Charles EL, Buffalo NY, inventors; Preparation Method of Poly-(D,L-lactide-co-glycolide) Nanoparticles with drugs. United States patent US 3297033. 1954 April.

Li H, Tran W, Hu Y, et al. A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres. Exp Eye Res 2006; 83(4): 824-33. DOI: https://doi.org/10.1016/j.exer.2006.04.014

Prasad Rao J, Geckeler Kurt E. Polymer Nanoparticles: Preparation techniques and size control parameters. Progr Polymer Sci 2011; 36: 887-913. http://dx.doi.org/10.1016/j.progpolymsci.2011.01.001 DOI: https://doi.org/10.1016/j.progpolymsci.2011.01.001

Helle A, Hirsjarvi S, Peltonen L, et al. Quantitative determination of drug encapsulation in poly(lactic acid) nanoparticles by capillary electrophoresis. J Chromatography. A 2008; 1178: 248-55. http://dx.doi.org/10.1016/j.chroma.2007.11.041 DOI: https://doi.org/10.1016/j.chroma.2007.11.041

Fessi H, Puisieux F, Devissaguet JP, et al. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 1989; 55: 1-4. http://dx.doi.org/10.1016/0378-5173(89)90281-0 DOI: https://doi.org/10.1016/0378-5173(89)90281-0

Seyler I, Appel M, Devissaguet JP, Legrand P, Barratt G. Macrophage activation by a lipophilic derivative of muramyldipeptide within nanocapsules: investigation of the mechanism of drug delivery. J Nanopart Res 1999; 1: 91-7. http://dx.doi.org/10.1023/A:1010016128378 DOI: https://doi.org/10.1023/A:1010016128378

Legrand P, Lesieur S, Bochot A, et al. Influence of polymer behaviour in organic solution on the production of polylactide nanoparticles by nanoprecipitation. Int J Pharm 2007; 344: 33-43. http://dx.doi.org/10.1016/j.ijpharm.2007.05.054 DOI: https://doi.org/10.1016/j.ijpharm.2007.05.054

Chang J, Jallouli Y, Kroubi M, et al. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. Int J Pharm 2009; 379: 285-92. http://dx.doi.org/10.1016/j.ijpharm.2009.04.035 DOI: https://doi.org/10.1016/j.ijpharm.2009.04.035

Nehilla BJ, Bergkvist M, Popat KC, Desai TA. Purified and surfactant-free coenzyme Q10-loaded biodegradable nanoparticles. Int J Pharm 2008; 348: 107-14. http://dx.doi.org/10.1016/j.ijpharm.2007.07.001 DOI: https://doi.org/10.1016/j.ijpharm.2007.07.001

Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci 2010; 351: 19-29. http://dx.doi.org/10.1016/j.jcis.2010.05.022 DOI: https://doi.org/10.1016/j.jcis.2010.05.022

Burkeev MZh, Tazhbayev YM, Zhaparova LZh, Zhappar NK. Poly-D,L-lactic acid as a polymeric carrier of antituberculosis drug preparation “Isoniazid”. In: Мateriály IX Mezinárodní védecko-praktiká conference “Moderní Vymoženosti védy-2013”. Praha, Publishing house “Education and Science; 2013: p.61-6. (in Russian)